How an Acquisition Hits the Three Financial Statements

Introduction

On December 14, 2023, Pfizer completed its acquisition of Seagen, paying $229 per share in cash. The fair value of what it paid was $44.2 billion. Between closing and year-end, Seagen contributed $120 million of revenue to Pfizer's income statement and a $746 million net loss, because Pfizer had to absorb deal costs and the first slices of purchase accounting charges. The balance sheet told a much bigger story: $20.8 billion of in-process research and development, $8.0 billion of other intangible assets, $16.1 billion of goodwill and $6.1 billion of net tax liabilities appeared on Pfizer's books overnight.

An acquisition is the largest single transaction most companies ever record, and it reaches the three statements in two distinct waves. At closing, almost everything happens on the balance sheet and in the investing section of the cash flow statement; the income statement barely moves. After closing, the purchase accounting choices made at closing flow into earnings for years, through amortization, depreciation of written-up assets, inventory step-ups and the cost of the financing. The trace below follows both waves with the method from tracing a transaction through the statements, using a simple example and then Pfizer's own disclosures.

Under the acquisition method in Accounting Standards Codification (ASC) 805, the buyer that gains control consolidates the target from the acquisition date. It records each identifiable asset acquired and liability assumed at fair value, including intangible assets the target never recorded, such as customer relationships, technology and brands. Whatever the buyer pays above the fair value of those identifiable net assets is goodwill. The target's own equity disappears: the buyer's statements show the target's assets and liabilities, not its shareholders' equity. The acquisition method itself is explained in the acquisition method for business combinations.

Purchase price allocation

The process of assigning the price paid in an acquisition to the identifiable assets acquired and liabilities assumed, measured at fair value, with the remainder recorded as goodwill. It determines the depreciation, amortization and deferred taxes the buyer will report after the deal.

Suppose a buyer pays $1,000 in cash for all of a target whose balance sheet shows $50 of cash, $550 of other assets and $200 of liabilities, so book equity of $400. In the allocation, the buyer writes property, plant and equipment (PP&E) up by $100 and recognizes $300 of intangible assets the target did not carry. Because this is a stock purchase, the tax basis of the assets does not change, so the $400 of write-ups creates a $100 deferred tax liability at 25%. Identifiable net assets at fair value are $700: the $400 of book equity, plus $400 of write-ups, less $100 of deferred tax. Goodwill is the remaining $300. On the buyer's consolidated statements at closing:

The income statement does not move at closing. The cash flow statement shows a single investing outflow of $950: the $1,000 price less the $50 of cash that came with the target. On the balance sheet, the buyer's cash falls by that $950, and the target's other assets arrive at $650, their $550 book value plus the $100 PP&E write-up, alongside $300 of new intangibles and $300 of goodwill. Liabilities rise by the target's $200 and the $100 deferred tax liability. Assets and liabilities each rise by $300 net, and the buyer's equity is unchanged: it has exchanged cash for a business of equal value.

Goodwill

The excess of the price paid for a business over the fair value of its identifiable net assets, representing expected synergies, the assembled workforce and other value that cannot be separately recognized. It is not amortized by public companies under US generally accepted accounting principles (US GAAP) but is tested for impairment at least annually.

How each fair value is estimated, and how goodwill emerges from the residual, are covered in purchase price allocation and goodwill creation and bargain purchases.

Paying With Cash, Debt or Stock

The way the price is funded changes the closing trace only on the financing side. The identifiable assets, goodwill and deferred taxes are the same whatever the currency:

A stock deal is the only one in which the buyer's equity rises at closing, and the only one with no cash price on the cash flow statement; the share issuance is disclosed among the non-cash investing and financing activities. A debt-funded deal leaves equity and the share count unchanged but adds interest expense afterwards; because the after-tax interest cost is often smaller than the share of earnings that new shareholders would claim, debt-funded acquisitions are more likely to raise earnings per share in the short term than stock-funded ones.

In a stock deal, the consideration is measured at the fair value of the shares on the closing date, not on the day the deal was announced. If the buyer's share price rises between signing and closing, the recorded price and the goodwill rise with it, even though the number of shares issued is unchanged; if it falls, both fall. A deal announced at one value can therefore enter the books at a materially different one, which is why the goodwill on stock-funded deals sometimes surprises investors who remember the headline price.

Buying Less Than All of the Target

Control, not full ownership, triggers consolidation. If the buyer acquires 80% of the target for $800, and the remaining 20% is worth $200, it still records all of the target's assets and liabilities at fair value, the same $650 of other assets, $300 of intangibles and $300 of liabilities, and the same $300 of goodwill, because US GAAP measures the minority stake at fair value. The difference sits in equity: a $200 noncontrolling interest appears alongside the parent's shareholders' equity, representing the minority owners' claim. After closing, consolidated net income includes all of the target's profit, and the minority's share is then deducted to arrive at net income attributable to the parent, the figure that drives earnings per share. The presentation is covered in noncontrolling interest.

Earnouts and Contingent Consideration

Part of the price is often contingent on the target's future performance. Under ASC 805, the buyer records an earnout at its fair value at closing, as part of the consideration, so it increases goodwill and creates a liability. Afterwards, changes in that fair value go through the income statement: if the target outperforms and the expected payment rises, the buyer records a loss, and if it underperforms, a gain, which can produce the odd result of a buyer reporting higher earnings because its acquisition is doing badly. When the earnout is paid, cash up to the amount recognized at closing is generally shown in financing activities if paid well after the deal, and any excess in operating activities. The mechanics are covered in earnouts and contingent consideration.

Deal Costs Hit the Income Statement

The one closing-date item that does reach the income statement is the cost of doing the deal. Under ASC 805, advisory, legal, accounting and other acquisition-related costs are expensed as incurred, not added to the price. A buyer that pays $20 of advisory fees reduces pre-tax income by $20, with the cash in operating activities; for tax, fees that facilitate a share purchase are usually added to the cost of the shares rather than deducted, so net income often falls by the full $20. Costs of issuing debt or shares to fund the deal are treated differently: they reduce the carrying amount of the debt or the proceeds recorded in equity. The distinction is covered in transaction costs and financing fees.

From the day after closing, the target's revenue and expenses flow into the buyer's consolidated income statement. So do the consequences of the purchase price allocation. Intangible assets with finite lives are amortized; written-up PP&E is depreciated at its higher value; inventory written up to fair value is charged to cost of goods sold as it is sold, depressing margins in the first months; and the deferred tax liability created at closing unwinds as the extra charges are recognized. Goodwill is not amortized under US GAAP for public companies, but is tested for impairment at least annually.

Continuing the example, suppose the $300 of intangibles is amortized over ten years and the $100 PP&E write-up depreciated over ten years. The incremental first-year effect of the purchase accounting alone is:

Net income falls by $30 a year, yet cash does not change at all. The $40 of extra depreciation and amortization is non-cash and, because the buyer purchased the target's shares, not deductible for tax, so the tax expense falls only through the $10 unwinding of the deferred tax liability, which saves no cash. Every year for ten years, purchase accounting reduces reported earnings by $30 while leaving the business's cash generation untouched. If the deal had been structured as an asset purchase, or with an election that steps up the tax basis, the write-ups would be depreciated and amortized for tax as well, over tax lives of their own, and would save cash tax instead, a difference explored in stock deals vs asset deals.

The Inventory Step-Up

One purchase accounting charge is concentrated in the first months. Acquired inventory is recorded at fair value, roughly its selling price less the costs and profit of selling it, which is usually well above the target's own cost. Suppose the target's inventory cost $80 and is valued at $100 in the allocation. When the goods are sold, cost of goods sold is $100 rather than $80, so gross profit is $20 lower than the target would have reported, and net income $15 lower after the deferred tax effect, with no cash consequence. Because inventory turns over within months, the charge disappears quickly, which is why acquirers report it as a separate item and bankers remove it from the first quarters' margins. Pfizer's first charge for Seagen inventory, described below, is this effect.

Financing Costs and Lost Interest

The funding choice reappears after closing. A debt-funded deal adds interest expense, reduced by its tax shield, to every year's income statement, with the interest paid in operating activities and principal repayments in financing. A cash-funded deal reduces interest income on the cash spent. A stock-funded deal adds no expense but increases the share count, diluting earnings per share. The combined effect of the target's earnings, purchase accounting, financing costs and new shares on the buyer's earnings per share is the subject of accretion and dilution analysis, set out in the Valuation guide's article on measuring the EPS impact.

Pfizer's 2023 annual report shows the closing wave at scale, in its provisional purchase price allocation:

Several features of the trace are visible. Nearly two-thirds of the price went to identifiable intangible assets, most of it in-process research and development, which is carried as an indefinite-lived asset until each project is completed or abandoned, then amortized or impaired. The $7.5 billion of developed technology rights, amortized over about 18 years, implies roughly $400 million of annual amortization. The net tax liability of $6.1 billion includes $7.5 billion for the tax effect of fair value adjustments, the deferred tax created because the stock purchase did not step up the tax basis, partly offset by deferred tax assets on which Seagen had carried a valuation allowance. And $16.1 billion of goodwill, not deductible for tax, captures expected synergies and the value of Seagen's assembled business.

On the cash flow statement, Pfizer reported $43.4 billion of acquisitions, net of cash acquired, in investing activities, funded largely by the $31 billion of bonds issued in May and by short-term borrowing. After closing, the first purchase accounting charges appeared: $109 million for acquired inventory sold at its stepped-up value, $25 million of intangible amortization and $2 million of extra depreciation between closing and year-end, alongside $614 million of restructuring, integration and acquisition-related costs.

Provisional Amounts and the Measurement Period

The word provisional matters. A buyer has up to one year from closing, the measurement period, to finalize its valuations, and Pfizer stated that its Seagen figures could change significantly as valuation work, inventory counts and tax filings were completed. Adjustments during that year typically move amounts between identifiable assets and goodwill. Under US GAAP they are recorded in the period in which they are identified, including any catch-up effect on depreciation or amortization, rather than by restating earlier periods. Analysts comparing a buyer's post-deal results should check the following year's filing for the final allocation before relying on the amortization implied by the first one.

For bankers, the two waves set the agenda for analyzing any acquirer. At closing, the questions are about the balance sheet: how much of the price went to goodwill, which is exposed to impairment if the deal disappoints; how much to finite-lived intangibles, which sets future amortization; and how the deal was funded, which sets leverage. Pfizer's total debt doubled in 2023, from $35.8 billion to $71.9 billion, and its goodwill rose from $51.4 billion to $67.8 billion, figures that shaped how lenders and rating agencies viewed the deal.

After closing, the questions are about earnings quality. Reported earnings fall because of non-cash purchase accounting charges, while cash earnings are unaffected by them; adjusted earnings remove the amortization but keep the financing cost. The first year also carries one-off items, such as inventory step-up charges, retention payments and integration costs, that will not recur. Separating these layers, and building pro forma figures as if the deal had happened at the start of the period, is how bankers compare an acquirer's performance before and after a deal, a process covered in pro forma financial statements.

When the Deal Disappoints

The goodwill recorded at closing is the part of the price most exposed to later write-downs. If the acquired business underperforms, the annual impairment test can force the buyer to reduce goodwill, a non-cash charge that is usually not deductible for tax, so it cuts net income by its full amount while leaving cash untouched. Large goodwill impairments years after a deal are therefore the accounting record of an acquisition that did not deliver what was paid for it, and their statement effects are traced in impairments and write-downs on the three statements.

The trace reduces an acquisition to a short sequence. At closing, cash or shares go out, the target's fair-valued assets and liabilities come in, and goodwill fills the gap, with only deal costs touching net income. Afterwards, the stepped-up assets wear out through amortization and depreciation, the deferred tax liability unwinds, and financing costs or new shares take their share of earnings. Every acquisition, from a bolt-on to a $44 billion pharmaceutical deal, follows that pattern.